There is a new possible treatment for Ulcerative Colitis in the pipelines, and it has shown to be very promising in initial trials. This new pill offers a way of controlling inflammation by promoting the production of microRNA which has been linked to strong anti-inflammatory activities. By using the ABX464 molecule to promote this RNA-124, Abivax can regulate the gene expression within the cells itself. Let’s take a look at this unique drug class and the positive results shown during phase 1 and 2 trials.
I know it may seem a bit confusing to understand how this drug works, and the full scientific explanation is a lot of information. But essentially, the ABX464 binds to a certain gene’s messenger RNA (mRNA), which is the molecule generated from DNA. The cells use this DNA as a template for various protein production in the body. By preventing the manufacturing of the specific proteins, you can limit the inflammation activity in the body thus lowering symptoms and improving intestinal wall health. Â
These initial trials began back in 2020, and had some really promising potential. In fact, 69% of patients were in clinical remission, and a whopping 94% benefited from a clinical response. In addition, 44% of patients had achieved endoscopic remission. Since these results were positive, the volunteers were offered to stay in the program for two full years. 22 of the 23 agreed, and now we are able to see some long-term efficacy and safety. Of which these did well in the two-year test, and even had patients producing normalized fecal calprotectin tests within the first year, which is the key marker of UC disease activity.Â
Based on the positive results from the initial trials as well as the Phase 2b trials, the drug company is conducting another open-label maintenance study from the volunteers in the 2b study to confirm its long-term effectiveness and safety after the two-year marker. What was a group of 23, has now expanded to 232 patients in the U.S, Canada, and 15 European countries? This will widen the genome, and will be a truer test of the drug’s efficacy across age groups and more diverse populations. An IND was granted to Abivax in January of 2020, and it has really taken off from there. In the future of Ulcerative Colitis treatment Abivax looks like an encouraging option for those who have failed other treatments. Keep an eye out for this new drug class in the next few years! Â
Want to check out the facts for your self? Click HERE & HERE for the articles used. Â
Note: * This is NOT an affiliate post. I do not receive anything for promoting or recommending products or services. *Â